alemtuzumab

基本解释

• 阿仑单抗

同根派生

英汉例句

• Two alemtuzumab and three Thymoglobulin patients suffered rejection episodes.
  阿仑单抗组有2例而抗胸腺细胞球蛋白组有3例发生排斥反应.
• Alemtuzumab is an immunosuppressive antibody that depletes normal T-cells as well as B-cells.
  阿仑单抗是一种针对T、B细胞的单克隆抗体。
• BACKGROUND.: An increase in the incidence of autoimmune diseases has been described in patients receiing alemtuzumab.
  背景：接受阿仑单抗免疫诱导治疗治疗患者的自身免疫性疾病发生率增加。
• One-year cumulatie graft surial was 85.7% for the alemtuzumab group and 87.5% for the Thymoglobulin group.
  1年累积生存率阿仑单抗组为85.;7%25;抗胸腺细胞球蛋白组为87
• Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
  阿仑单抗;一种人源性抗-CD52抗体;在免疫耐受诱导方案中效果显著;需要最少的免疫抑制维持药物.